{
    "2019-01-18": [
        [
            {
                "time": "2019-01-18",
                "original_text": "Eli Lilly Slides as Sarcoma Treatment Fails in Phase 3 Trial",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Sarcoma",
                        "Treatment",
                        "Phase 3",
                        "Trial",
                        "Fails"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-01-18",
                "original_text": "Highly Rated Pharma Dips On Drug Failure â€” Is Its Buy Point At Risk?",
                "features": {
                    "keywords": [
                        "Pharma",
                        "Drug",
                        "Failure",
                        "Buy Point",
                        "Risk"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-01-18",
                "original_text": "Eli Lilly News: LLY Stock Falls on Sarcoma Study Failure",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "LLY",
                        "Stock",
                        "Falls",
                        "Sarcoma",
                        "Study",
                        "Failure"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-01-18",
                "original_text": "Lilly cancer drug fails key trial, will no longer be prescribed",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Cancer",
                        "Drug",
                        "Fails",
                        "Key Trial",
                        "Prescribed"
                    ],
                    "sentiment_score": -0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-01-18",
                "original_text": "Lilly's Sarcoma Drug Combo Proves Ineffective in Trials",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Sarcoma",
                        "Drug",
                        "Combo",
                        "Ineffective",
                        "Trials"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-01-18",
                "original_text": "Here is Why Growth Investors Should Buy Lilly (LLY) Now",
                "features": {
                    "keywords": [
                        "Growth",
                        "Investors",
                        "Buy",
                        "Lilly",
                        "LLY"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-01-18",
                "original_text": "FDA Turns Down IMMU's Breast Cancer Drug, ZYME/LLY Deal Progresses, ZFGN Abuzz",
                "features": {
                    "keywords": [
                        "FDA",
                        "IMMU",
                        "Breast Cancer",
                        "Drug",
                        "ZYME",
                        "LLY",
                        "Deal",
                        "Progresses",
                        "ZFGN",
                        "Abuzz"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-01-18",
                "original_text": "Dow jumps 160 points as stock market set to end week with solid gains on China-trade optimism",
                "features": {
                    "keywords": [
                        "Dow",
                        "Jumps",
                        "Points",
                        "Stock Market",
                        "Solid Gains",
                        "China-Trade",
                        "Optimism"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "market"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-01-18",
                "original_text": "Lilly's cancer therapy Lartruvo fails study, shares drop",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Cancer",
                        "Therapy",
                        "Lartruvo",
                        "Fails",
                        "Study",
                        "Shares",
                        "Drop"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-01-18",
                "original_text": "Eli Lilly shares slide premarket on news of failed trial for sarcoma treatment",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Shares",
                        "Slide",
                        "Premarket",
                        "Failed",
                        "Trial",
                        "Sarcoma",
                        "Treatment"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}